Here are the 10-K annual reports from Aimei Health Technology Co., Ltd (AFJK) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow AFJK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AFJK filings page.
Aimei Health Technology Co., Ltd., a Cayman Islands special purpose acquisition company listed on Nasdaq as AFJK, reports on its blank-check operations for the year ended December 31, 2025 and its efforts to complete an initial business combination.
The SPAC raised $69,690,000 into a U.S. trust account from its December 2023 IPO and concurrent private placement, after selling 6,900,000 public units at $10.00 each and 332,000 private units. It has been granted up to 36 months from the IPO closing to complete a business combination, with monthly extension loans funded by its sponsor and United Hydrogen.
Aimei has signed a definitive Business Combination Agreement with United Hydrogen Group Inc., whose operations are conducted through PRC subsidiaries, and obtained shareholder approval in November 2025. Closing remains subject to multiple conditions, including Nasdaq listing standards, minimum net tangible assets, and completion of a PRC CSRC filing by United Hydrogen under the Trial Measures for overseas offerings, which is under review.
The filing highlights significant legal and operational risks if the combined company’s main operations are in China, including evolving CSRC and cybersecurity oversight, foreign exchange controls, dividend restrictions, and the possibility that PRC authorities could delay, condition, or restrict offshore listings or capital flows, potentially affecting the value and liquidity of AFJK’s ordinary shares.